Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.60 USD
Change Today -0.77 / -4.43%
Volume 472.6K
NXTM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

nxstage medical inc (NXTM) Snapshot

Open
$17.15
Previous Close
$17.37
Day High
$17.42
Day Low
$16.58
52 Week High
04/27/15 - $19.63
52 Week Low
09/16/14 - $11.50
Market Cap
1.1B
Average Volume 10 Days
571.4K
EPS TTM
$-0.36
Shares Outstanding
63.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NXSTAGE MEDICAL INC (NXTM)

Related News

No related news articles were found.

nxstage medical inc (NXTM) Related Businessweek News

No Related Businessweek News Found

nxstage medical inc (NXTM) Details

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product includes the System One, a portable hemodialysis system used for the treatment of acute and chronic kidney failure, and fluid overload. The company operates in three segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the NxStage System One and PureFlow SL dialysate preparation equipment, and sale of disposable products in the home and critical care markets. The home market focuses on the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting, and critical care market on the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers; and needles for apheresis. The Services segment provides dialysis services to patients at NxStage Kidney Care dialysis centers. NxStage Medical, Inc. markets its products through direct sales and distributors to hospitals and dialysis centers in the United States and internationally. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

3,400 Employees
Last Reported Date: 02/26/15
Founded in 1998

nxstage medical inc (NXTM) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $496.9K
President
Total Annual Compensation: $338.6K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $305.6K
President of Nxstage Kidney Care
Total Annual Compensation: $306.4K
Senior Vice President of Quality Assurance, R...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

nxstage medical inc (NXTM) Key Developments

Nxstage Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter and revises earnings guidance for the Full Year 2015

NxStage Medical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $80,316,000 compared to $74,083,000 a year ago. Loss from operations was $5,116,000 compared to $6,651,000 a year ago. Net loss before income taxes was $5,321,000 compared to $6,863,000 a year ago. Net loss attributable to stockholders of the company was $5,327,000 or $0.08 basic and diluted per share compared to $7,113,000 or $0.12 basic and diluted per share a year ago. The revenue represents an 8% increase over the prior year. The growth was driven by strong performance in the System One segment, which increased 17% compared to last year and includes fastest-growing businesses, Home and Critical Care. For the six months, the company reported revenues of $159,798,000 compared to $146,304,000 a year ago. Loss from operations was $10,695,000 compared to $11,440,000 a year ago. Net loss before income taxes was $10,877,000 compared to $11,827,000 a year ago. Net loss attributable to stockholders of the company was $10,985,000 or $0.17 basic and diluted per share compared to $12,388,000 or $0.20 basic and diluted per share a year ago. Net cash used in operating activities was $2,384,000 against $14,213,000 a year ago. For the full-year of 2015, the company expects, net loss guidance to be in a range of $18.0 million to $20.0 million versus previous guidance for a net loss in the range of $20.0 million to $24.0 million, and dramatically reducing targeted annual cash usage to approximately $10 million, which is about half original projection and one-third of cash usage in 2014. For the third quarter, the company expects revenue to be between $82 million and $83 million, and a net loss in the range of $4.5 million to $5.5 million. The Company's net loss guidance reflects expectations for continued operating income from the Products Business offset by the company's continued investment in NxStage Kidney Care.

Nxstage Medical, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:00 PM

Nxstage Medical, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:00 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Jeffrey H. Burbank, Founder, Chief Executive Officer and Director, Matthew W. Towse, Chief Financial Officer and Senior Vice President.

Nxstage Medical, Inc. Presents at William Blair & Company's 31st Annual Growth Stock Conference, Jun-15-2011

Nxstage Medical, Inc. Presents at William Blair & Company's 31st Annual Growth Stock Conference, Jun-15-2011 . Venue: Four Seasons Hotel, 120 East Delaware Place, Chicago, Illinois, United States. Speakers: Jeffrey H. Burbank, Founder, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NXTM:US $16.60 USD -0.77

NXTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $14.56 USD -0.20
ICU Medical Inc $110.00 USD -3.52
Merit Medical Systems Inc $22.54 USD -0.21
Orthofix International NV $36.94 USD -0.54
RTI Surgical Inc $6.14 USD -0.24
View Industry Companies
 

Industry Analysis

NXTM

Industry Average

Valuation NXTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NXSTAGE MEDICAL INC, please visit www.nxstage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.